Modality
Degrader
MOA
AuroraAi
Target
AuroraA
Pathway
Notch
Breast CaUC
Development Pipeline
Preclinical
~Jul 2013
→ ~Oct 2014
Phase 1
~Jan 2015
→ ~Apr 2016
Phase 2
~Jul 2016
→ ~Oct 2017
Phase 3
Jan 2018
→ May 2029
Phase 3Current
NCT04126936
1,263 pts·UC
2018-01→2029-05·Recruiting
1,263 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-05-243.1y awayPh3 Readout· UC
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P3
Recruit…
Catalysts
Ph3 Readout
2029-05-24 · 3.1y away
UC
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04126936 | Phase 3 | UC | Recruiting | 1263 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA |